Stocks in Focus: Construction, Pharma, Railway, and Renewable Energy Stocks to Watch
Stocks to watch today: Signature Global, IndusInd Bank, pharma, railway and renewable energy stocks are expected to be in focus as investors await key developments in these sectors.
Construction Contracts Awarded to KEC International and NCC
Signature Global has awarded construction contracts worth Rs 920 crore to KEC International Ltd (Rs 460 crore) and NCC (Rs 460 crore) for its premium housing project ‘Sarvam at DXP Estate’ in Gurugram.
KEC International Limited will construct 6 residential towers within 36 months, while NCC Limited will construct 5 residential towers within the same timeframe.
Key Details of the Construction Contracts
The construction work is expected to commence by the end of the third quarter of FY27 and will comprise 1,798 residential units with a development area of approximately 5 million sq. ft.
IndusInd Bank Receives RBI Approval for Stockbroking Subsidiary
- IndusInd Bank has received approval from the Reserve Bank of India (RBI) to set up a wholly owned subsidiary to undertake stockbroking business.
- The bank has also been permitted to infuse equity capital into the new subsidiary, subject to additional conditions mentioned in the RBI letter.
- Shares of IndusInd Bank closed 1.9 per cent higher at ₹1,025 on the BSE.
Pharma Firms in Focus
Novartis India Terminates Distribution Agreement with Dr Reddy’s Laboratories
Novartis India has terminated its Distribution and Promotion Agreement with Dr Reddy’s Laboratories Ltd, ending a partnership that granted the latter exclusive rights to promote and sell certain products.
The termination, effective on September 30, 2026, allows Novartis India to reacquire exclusivity and secure direct market access for these products, marking a strategic shift in its go-to-market approach.
Emcure Pharma Receives USFDA Inspection Report
Emcure Pharma informed the exchanges that it has received the Establishment Inspection Report (EIR) following the USFDA inspection of the company’s formulations facility located at Sanand, Ahmedabad.
The US drug regulator conducted this inspection from May 06, 2026, to May 15, 2026, and has classified the inspection status of the said facility as Voluntary Action Indicated (VAI) and accordingly, the inspection stands closed.
AstraZeneca Pharma India Receives Approval for Enhertu
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India, to import Enhertu (Trastuzumab Deruxtecan) for sale and distribution in India.
The approval is for an additional indication of the drug in the treatment of HER2-positive breast cancer, according to its disclosure to the stock exchanges.
Gland Pharma Executes Strategic Manufacturing Agreement
Gland Pharma has announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with one of the leading global pharmaceutical companies for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets.
The partnership establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development.
Railway Stocks
RITES Ltd Signs MoU with Hindustan Petroleum Corporation Limited
RITES Ltd has signed a Memorandum of Understanding with Hindustan Petroleum Corporation Limited to provide end-to-end consultancy services for the development of railway siding infrastructure across HPCL’s facilities.
Under the agreement, the PSU railway major will offer consultancy services spanning the entire project lifecycle for railway siding projects, from concept to commissioning.
Neetu Yoshi Limited Commences Commercial Production
Neetu Yoshi Limited will commence commercial production at its new manufacturing facility in Haridwar, Uttarakhand, on September 13, 2026.
The expansion, funded entirely by Initial Public Offering (IPO) proceeds, is designed to double the company’s manufacturing capabilities.
Power & Energy Counters
Fujiyama Power Systems Limited Commences 2 GW Power-Electronics Manufacturing Facility
Fujiyama Power Systems Limited (Fujiyama) has commissioned a 2 GW power-electronics manufacturing facility in Ratlam, Madhya Pradesh.
The facility will manufacture a wide range of power electronics products, including solar inverters, UPS systems and other related solutions, the company said in an exchange filing on Friday.
NTPC Green Energy Emerges as Successful Bidder for BESS Projects
NTPC Green Energy Ltd has emerged as the successful bidder in the e-reverse auction conducted by West Bengal State Electricity Distribution Company Ltd (WBSEDCL) for the development of standalone Battery Energy Storage System (BESS) projects in West Bengal.
NTPC Green Energy secured 200 MW/800 MWh of BESS capacity at a discovered tariff of ₹4.35 lakh per MW per month under the tender.
Juniper Green Energy Emerges as Winning Bidder for 230 MW Solar Project
Juniper Green Energy on Friday said it has emerged as the winning bidder for a 230 MW project under the Solar Energy Corporation of India’s 1,000 MW firm-and-dispatchable renewable energy round-the-clock tender.
The company secured the capacity at a tariff of 5.26 per unit, a company statement said.
Key Takeaways
- Signature Global has awarded construction contracts worth Rs 920 crore to KEC International Ltd and NCC for its premium housing project ‘Sarvam at DXP Estate’ in Gurugram.
- IndusInd Bank has received approval from the RBI to set up a wholly owned subsidiary to undertake stockbroking business.
- Gland Pharma has executed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets.
FAQs
What is the significance of Signature Global’s construction contracts?
The construction contracts worth Rs 920 crore are significant as they will contribute to the development of Signature Global’s premium housing project ‘Sarvam at DXP Estate’ in Gurugram.
What is the impact of IndusInd Bank’s RBI approval on its stock price?
The RBI approval has a positive impact on IndusInd Bank’s stock price, with shares closing 1.9 per cent higher at ₹1,025 on the BSE.
What is the significance of Gland Pharma’s strategic Manufacturing and Supply Agreement?
The agreement establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development.
Conclusion
The stocks mentioned in this article are expected to be in focus as investors await key developments in these sectors.
Investors are advised to keep a close eye on the developments in these sectors and make informed decisions based on their research and analysis.
